Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PIK3C3 | Q8NEB9 | 6/20 | 0.42 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.41 |
| ▸ | SLC40A1 | Q9NP59 | 3/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1830081 | 0.95 | MEN1 (0.42) | MEN1KMT2APIK3C3PFKFB3SLC40A1 | |
| SCHEMBL1378919 | 0.81 | MEN1 (0.43) | MEN1KMT2APFKFB3SLC40A1NR3C1 | |
| SCHEMBL1381278 | 0.81 | MEN1 (0.43) | MEN1KMT2APFKFB3SLC40A1NR3C1 | |
| SCHEMBL1375525 | 0.80 | PIK3C3 (0.47) | MEN1KMT2APIK3C3 | |
| SCHEMBL1382252 | 0.76 | HSD11B1 (0.62) | MEN1KMT2APIK3C3SLC40A1 | |
| SCHEMBL1381843 | 0.74 | ALPL (0.52) | — | |
| SCHEMBL1381599 | 0.74 | ALDH1A1 (0.50) | MEN1KMT2ASCN9A | |
| SCHEMBL1381446 | 0.72 | PIK3C3 (0.54) | KMT2APIK3C3 | |
| SCHEMBL1381363 | 0.72 | HSD11B1 (0.59) | MEN1KMT2APIK3C3SLC40A1 | |
| SCHEMBL1379502 | 0.72 | HSD11B1 (0.59) | MEN1KMT2APIK3C3SLC40A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4809339-B2 | — | — | 2011-11-09 | — | — | JP | claimed |
| EP-1763517-B1 | PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-05-11 | — | — | EP | claimed |
| US-7507733-B2 | 11b-HSD1 inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | claimed |
| EP-1763517-A2 | PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-21 | — | — | EP | claimed |
| WO-2006000371-A2 | PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-01-05 | — | — | WO | claimed |
| US-20050288308-A1 | 11B-HSD1 inhibitors for the treatment of diabetes | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-29 | — | — | US | claimed |
| EP-1763517-B1 | PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-05-11 | — | — | EP | disclosed |
| US-7507733-B2 | 11b-HSD1 inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1763517-A2 | PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-21 | — | — | EP | disclosed |
| WO-2006000371-A2 | PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-01-05 | — | — | WO | disclosed |
| US-20050288308-A1 | 11B-HSD1 inhibitors for the treatment of diabetes | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288308-A1 | 11B-HSD1 inhibitors for the treatment of diabetes | HSD11B1, HSD17B1, HSD3B1 | MEN1 1164/4885KMT2A 3712/4885PIK3C3 4103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.